Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event By: Taysha Gene Therapies, Inc. via Business Wire January 03, 2022 at 07:00 AM EST Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that RA Session II, President, Founder and CEO of Taysha, will participate in two panel discussions during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title: Gene Therapy: Reaching its Full Potential Date: Thursday, January 6, 2022 Time: 11:00 AM ET Webcast: https://wsw.com/webcast/lifesci3/panel8/2389200 Title: Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders Date: Thursday, January 6, 2022 Time: 2:00 PM ET Webcast: https://wsw.com/webcast/lifesci3/panel10/2456850 A webcast of the panels will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005109/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event By: Taysha Gene Therapies, Inc. via Business Wire January 03, 2022 at 07:00 AM EST Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that RA Session II, President, Founder and CEO of Taysha, will participate in two panel discussions during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title: Gene Therapy: Reaching its Full Potential Date: Thursday, January 6, 2022 Time: 11:00 AM ET Webcast: https://wsw.com/webcast/lifesci3/panel8/2389200 Title: Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders Date: Thursday, January 6, 2022 Time: 2:00 PM ET Webcast: https://wsw.com/webcast/lifesci3/panel10/2456850 A webcast of the panels will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005109/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that RA Session II, President, Founder and CEO of Taysha, will participate in two panel discussions during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title: Gene Therapy: Reaching its Full Potential Date: Thursday, January 6, 2022 Time: 11:00 AM ET Webcast: https://wsw.com/webcast/lifesci3/panel8/2389200 Title: Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders Date: Thursday, January 6, 2022 Time: 2:00 PM ET Webcast: https://wsw.com/webcast/lifesci3/panel10/2456850 A webcast of the panels will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005109/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com